Respiratory | boehringer-ingelheim.ca

Lung Cancer

Finding out more about therapy goals in NSCLC

An introduction to the work we’ve been doing with physicians and patients

Watch the video on
Finding out more about therapy goals in NSCLC
Human Pharmaceuticals

Oncology

Read moreon
Oncology
NEWS RELEASE 09 May 2016

The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer

Read more on
The Lancet Oncology publishes head-to-head study comparing first and second generation targeted therapies in treatment of EGFR-mutation positive non-small cell lung cancer
NEWS RELEASE 26 Nov 2015

Boehringer Ingelheim (Canada) Ltd.’s Targeted Lung Cancer Therapy, GIOTRIF^{^®} (afatinib), Recognized with Prestigious Prix Galien Canada – Innovative Product Award

Read more on
Boehringer Ingelheim (Canada) Ltd.’s Targeted Lung Cancer Therapy, GIOTRIF^{^®} (afatinib), Recognized with Prestigious Prix Galien Canada – Innovative Product Award
NEWS RELEASE 17 Apr 2015

New Study of Canadian Oncologists Shines Light on Lung Cancer Mutation Testing and Treatment Trends

Read more on
New Study of Canadian Oncologists Shines Light on Lung Cancer Mutation Testing and Treatment Trends
NEWS RELEASE 08 Jul 2014

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

Read more on
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
NEWS RELEASE 29 May 2014

New Analysis Shows Afatinib* Demonstrates Significant Overall Survival in the First-Line Treatment of Lung Cancer Patients with Most Common Epidermal Growth Factor Receptor (EGFR) Mutation

Read more on
New Analysis Shows Afatinib* Demonstrates Significant Overall Survival in the First-Line Treatment of Lung Cancer Patients with Most Common Epidermal Growth Factor Receptor (EGFR) Mutation
NEWS RELEASE 07 Nov 2013

GIOTRIF^{^®} (afatinib) approved by Health Canada as a treatment for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) who are tyrosine kinase inhibitor naïve

Read more on
GIOTRIF^{^®} (afatinib) approved by Health Canada as a treatment for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) who are tyrosine kinase inhibitor naïve
NEWS RELEASE 03 Jun 2013

More Proof Lung Cancer is Not One Disease: New Investigational Treatment, Nintedanib* Plus Chemotherapy, Extends Life of Lung Cancer Patients With Adenocarcinoma

Read more on
More Proof Lung Cancer is Not One Disease: New Investigational Treatment, Nintedanib* Plus Chemotherapy, Extends Life of Lung Cancer Patients With Adenocarcinoma
NEWS RELEASE 16 May 2013

Lung Cancer, Not One Disease: Diverse Patients Need Personalized Treatments, Two New Studies Show

Read more on
Lung Cancer, Not One Disease: Diverse Patients Need Personalized Treatments, Two New Studies Show